Physicians over-relying on a commonly used laboratory test can miss liver cirrhosis

Max Cook
December 17, 2021
Dr. Don Rockey, director of the Digestive Disease Research Core Center at MUSC
Dr. Don Rockey, director of the Digestive Disease Research Core Center

A recent study at the Medical University of South Carolina’s (MUSC) Digestive Disease Research Core Center (DDRCC) provides insight into why physicians should be cautious when using a certain liver function test to diagnose alcoholic cirrhosis.

Alcoholic cirrhosis affects around 1 in 400 adults in the U.S. It is an advanced form of liver disease, which occurs when chronic ethanol use leads to inflammation and cirrhosis or scarring of the liver. Less than 50% of people diagnosed with advanced liver disease due to cirrhosis survive for one year, and so early diagnosis is crucial. Although cirrhosis is generally not a reversible condition, early diagnosis provides physicians with an opportunity to encourage cessation of drinking and offer treatment that can reduce symptoms and increase life expectancy.

“The core message here is that if you just look at the test, you’ll miss the diagnosis."

-- Dr. Don Rockey, DDRCC director

A common method to diagnose patients with alcoholic cirrhosis is to look for elevated levels of enzymes known as  aminotransferases in the liver. However, the MUSC study, published in The American Journal of Medical  Sciences, found that patients with alcoholic cirrhosis have nearly normal levels of aminotransferases. In this study, liver function test results of 78 patients with alcoholic cirrhosis revealed

The study’s findings are important because physicians who rely only on these tests can fail to diagnose alcoholic cirrhosis, said MUSC Health gastroenterologist and DDRCC director Don Rockey, M.D., who led the study.

In his own practice, Rockey has often observed that his patients with advanced liver disease have normal results on this test.

“We would see these patients with advanced disease and complications, yet their liver tests seemed to be normal. So, if you just looked at their liver tests, you’d say, ‘Oh no problem,’ but in fact, that wasn’t the case,” said Rockey.   

Diagram showing the potential reversibility of fibrosis. Originally published in the New England Journal of Medicine in 2015. Available at https://www.nejm.org/doi/full/10.1056/NEJMra1300575? 
The reversibility of liver fibrosis or scarring. Originally published in an article in the New England Journal of Medicine, available at https://www.nejm.org/doi/full/10.1056/NEJMra1300575?.

Often, patients may show subtle signs and symptoms in the early stages of alcoholic cirrhosis. However, if physicians look only at the laboratory results and not the patient, they are going to be “faked out,” said Rockey.

“Doctors need to be paying attention to the history, the physical examination, the whole clinical picture,” he said.  

Physicians should also be aware of tools that are available to diagnose cirrhosis, said Rockey. Noninvasive diagnostic tools include cross-sectional imaging, CT scans, MRI scans and especially the new technique – elastography. Rockey explained that elastography is a simple, noninvasive and convenient way to assess fibrosis and scarring in the liver. This test, available at MUSC and other tertiary care centers, can be performed easily in clinics or at the patient’s bedside.

Rockey said that the next step is to educate as many providers as possible and spread the word. While physicians who specialize in gastroenterology may understand that these laboratory tests are not always reliable, it is important to get this information out to a wide variety of practitioners.

“The core message here is that if you just look at the test, you’ll miss the diagnosis,” he said.

 Reference

Sullivan MK, Daher HB, Rockey DC. Normal or Near Normal Aminotransferase Levels in Patients with Alcoholic Cirrhosis. Am J Med Sci. 2021 Oct 4:S0002-9629(21)00355-4. doi: 10.1016/j.amjms.2021.09.012. Epub ahead of print. PMID: 34619146.

 

About the Author

Max Cook
Max Cook is a Ph.D. student and science communications intern at MUSC's College of Graduate Studies. He is interested in neurodegenerative research and works in Dr. Gavin Wang's lab.

Keywords: Research, Digestive Disease Research Core Center